Brief: Innate Pharma: Efficacy And Safety Results Of NK Cell Engager SAR443579/IPH6101

Innate Pharma SA

11/12/2023 06:03

Dec 11 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA SHARES EFFICACY AND SAFETY PHASE 1 /2
RESULTS OF
NK CELL ENGAGER SAR443579 / IPH6101 DEVELOPED BY SANOFI AT ASH
2023
    * INNATE PHARMA SHARES EFFICACY AND SAFETY PHASE 1 /2
RESULTS OF
NK CELL ENGAGER SAR443579 / IPH6101 DEVELOPED BY SANOFI AT ASH
2023
    * SAR443579/IPH6101, ANKET® PLATFORM LEAD ASSET, IS A
FIRST-IN-CLASS NKP46/CD16-BASED NK CELL ENGAGER TARGETING CD123
FROM A JOINT RESEARCH COLLABORATION BETWEEN INNATE PHARMA AND
SANOFI, UNDER DEVELOPMENT BY SANOFI
    * SAR443579 INDUCED CLINICAL BENEFIT IN PATIENTS WITH R/R
AML WITH
5 COMPLETE REMISSIONS (4 CR / 1 CRI) ACHIEVED AT 1 MG/KG, AND
WAS WELL TOLERATED UP TO DOSES OF 6 MG/KG
    * SAR443579 DEMONSTRATED DURABLE RESPONSES WITH TWO
RESPONDERS
REMAINING IN REMISSION BEYOND 8.8 AND 12.2 MONTHS OF TREATMENT

Source text for Eikon:  ID:nBwRDwhPa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))